Compare Crispr Therapeutics AG (CRSP) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Deere & Company — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while Deere & Company trades at $618 (market cap $166.81B). The key difference: Deere & Company is far larger — about 31.9× Crispr Therapeutics AG's market cap, and Deere & Company pays a 1.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | DE | |
|---|---|---|
Market Cap | $5.23B | $166.81B |
Sector | Health | Industrials |
52-Week High | $76.78 | $662.49 |
52-Week Low | $44.34 | $439.11 |
Enterprise Value | $3.65B | $221.63B |
Dividend Yield | — | 1.05% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
